Hemogenyx Pharmaceuticals plc develops clinical-stage biopharmaceutical therapies for blood and autoimmune diseases. Company news centers on HG-CT-1, its CAR-T cell therapy program for relapsed or refractory acute myeloid leukemia, including FDA IND reporting, clinical development updates, product stability work and lentiviral-vector manufacturing processes.
Recurring announcements also cover the company's CDX and CBR product candidates, platform technologies used for novel product development, and capital-market actions such as equity issuance, warrant exercises, prospectus publication, total voting rights and admissions of ordinary shares to trading on the London Stock Exchange.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.